YOLFTbeta
Biofrontera Inc

Biofrontera Inc

BFRI · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

0.7001USD-0.23 (-24.39%)

Price History

Full chart

Market Stats

Previous Close0.9259
Open0.96
Day Range0.6825 – 0.96
52-Week Range0.5547 – 1.66
Volume874.94K
Market Cap17.82M
P/E (TTM)0.00
Forward P/E13.00
EPS-0.45
Dividend Yield0.00%
Beta0.84
50-Day Avg1.31
200-Day Avg1.01

About

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Hermann Luebbert Ph.D.
  • Employees84
  • Headquarters660 Main Street, Woburn, MA, United States, 01801, USA
  • Websitehttps://www.biofrontera-us.com

Leadership

  • Dr. Hermann Luebbert Ph.D.CEO, President & Chairman · b. 1956
  • Mr. Eugene Frederick Leffler IIIChief Financial Officer · b. 1985
  • Mr. George P. JonesChief Commercial Officer · b. 1973
  • Ms. Erica F. Gates CPA, M.B.A.VP of Finance & Principal Accounting Officer
  • Mr. Jon Lyons M.B.A., Ph.D.Vice President of Scientific & Medical Affairs
  • Mr. Daniel Hakansson J.D.Senior Corporate Counsel
  • Ms. Samantha WiddicombeSenior Vice President of Sales & Strategic Accounts

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue26.18M18.85M24.10M28.67M34.07M37.30M41.70M
Growth (%)--28.01%+27.86%+18.98%+18.82%+9.49%+11.80%
Cost of Revenue12.41M9.07M12.74M15.19M17.44M18.61M8.90M
Gross Profit13.77M9.78M11.36M13.49M16.63M18.70M32.80M
Gross Margin52.61%51.90%47.13%47.04%48.80%50.12%78.65%
Operating Expense28.70M19.39M36.56M32.07M39.30M35.91M41.95M
Operating Income-14.92M-9.61M-25.20M-18.58M-22.68M-17.21M-9.15M
Operating Margin-57.00%-50.96%-104.57%-64.80%-66.56%-46.14%-21.94%
EBITDA-8.15M-7.46M-36.76M934.00K-18.45M-14.44M-9.19M
EBITDA Margin-31.12%-39.60%-152.52%3.26%-54.16%-38.71%-22.04%
Net Income-10.98M-10.99M-37.71M-640.00K-20.13M-17.76M-10.54M
Net Income Margin-41.95%-58.29%-156.49%-2.23%-59.09%-47.61%-25.26%
R&D---077.00K2.09M3.72M
R&D as % of Total Revenue---0.00%0.23%5.60%8.92%
Interest Expense2.16M2.90M360.00K370.00K600.00K2.11M452.00K
Interest Expense % of Total Revenue8.25%15.37%1.49%1.29%1.76%5.65%1.08%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets28.75M24.14M53.22M50.88M27.93M22.10M28.56M
Total Liabilities58.93M18.31M41.88M27.01M23.14M17.67M18.08M
Total Equity-30.18M5.83M11.34M23.88M4.79M4.43M10.48M
Cash7.30M8.08M24.55M17.21M1.34M5.91M6.39M
Total Debt38.20M--1.35M5.40M4.92M6.16M
Net Debt30.90M-8.08M-24.55M-15.86M4.06M-983.00K-231.00K

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-37.68M-12.37M-26.71M-16.20M-24.89M-10.27M-13.36M
Investing Cash Flow25.39M-11.00K-11.00K-5.16M619.00K-3.00K3.00M
Financing Cash Flow16.40M13.19M43.19M14.02M8.41M14.84M10.85M
Capital Expenditure538.00K11.00K11.00K38.00K5.00K60.00K2.00K
Free Cash Flow-38.22M-12.37M-26.73M-16.24M-24.90M-10.33M-13.36M
FCF to OCF101.43%100.00%100.04%100.23%100.02%100.58%100.01%

Earnings

Report DateJul 6, 2021Nov 30, 2021Dec 31, 2021Apr 8, 2022Aug 12, 2022Nov 14, 2022Mar 8, 2023May 12, 2023Aug 11, 2023Nov 9, 2023Mar 15, 2024May 15, 2024Aug 14, 2024Nov 13, 2024Mar 13, 2025May 15, 2025Aug 13, 2025Nov 12, 2025Mar 19, 2026May 14, 2026Aug 13, 2026Nov 11, 2026
EPS Estimate0.00-11.60-0.18-3.60-6.80-5.80-0.11-3.40-4.08-3.34-0.85-1.17-0.35-0.94-0.07-0.14-0.39-0.560.10-0.05-0.17-0.33
EPS Actual-0.51-9.66-0.15-6.11-8.63-5.24-0.14-3.22-6.07-3.16-0.68-2.88-1.08-0.81-0.23-0.47-0.57-0.570.50-0.41-0.05-
Surprise-16.72%16.67%-69.72%-26.91%9.66%-27.27%5.29%-48.77%5.39%20.00%-146.15%-208.57%13.83%-231.43%-235.71%-46.15%-1.79%400.00%-720.00%70.59%-
Timing-Pre-market-Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-market

Key Statistics & Ratios

Market Cap17.82M
Enterprise Value20.21M
Trailing P/E0.00
Forward P/E13.00
Price / Sales0.39
Price / Book2.92
EPS-0.45
Book Value0.419
Revenue (TTM)46.17M
Gross Profit (TTM)36.59M
EBITDA-5.97M
Profit Margin-13.79%
Operating Margin-4.37%
Return on Equity-988.35%
Return on Assets-17.45%
Shares Outstanding14.85M
Shares Float11.84M
Beta0.84
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 6.00
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
20.72%
Insiders
11.99%
Retail / Other
67.29%

Top Institutional Holders

  • Rosalind Advisors, Inc.
    1.16M7.84%
  • AIGH Capital Management, LLC
    739.91K4.98%
  • Geode Capital Management, LLC
    109.30K0.74%
  • Citadel Advisors Llc
    104.94K0.71%
  • Vanguard Fiduciary Trust Co
    61.70K0.42%
  • Vanguard Capital Management, LLC
    52.25K0.35%
  • Susquehanna International Group, LLP
    38.57K0.26%
  • XTX Topco Ltd
    22.49K0.15%
  • Citigroup Inc
    11.84K0.08%
  • Sanctuary Advisors, LLC
    10.20K0.07%
  • GSA Capital Partners LLP
    10.02K0.07%
  • BlackRock Inc
    4.62K0.03%
  • UBS Group AG
    1.54K0.01%
  • SBI Securities Co Ltd
    3050.00%
  • Jane Street Group LLC
    00.00%
  • TWO SIGMA SECURITIES, LLC
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    53.65K0.36%
  • Fidelity Series Total Market Index
    7.49K0.05%
  • Fidelity Total Market Index
    4220.00%

Stock Splits

  • Jul 5, 20231:20